

Michele Navarra¹*, Carmen Mannucci², Marisa Delbò³ and Gioacchino Calapai²

¹ Department of Drug Sciences and Products for Health, University of Messina, Messina, Italy

² Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

³ Italian Medicines Agency, Rome, Italy

Edited by:

Juei-Tang Cheng, Chang Jung Christian University, Taiwan

Reviewed by:

Fang-Rong Chang, Kaohsiung Medical University, Taiwan Luisa Pistelli, University of Pisa, Italy Subhalakshmi Ghosh, Jadavpur University, India

*Correspondence:

Michele Navarra, Department of Drug Sciences and Products for Health, University of Messina, Viale Annunziata, I-98168 Messina, Italy e-mail: mnavarra@unime.it

INTRODUCTION

Bergamot is the common name for Citrus bergamia Risso et Poiteau, a plant belonging to the Rutaceae family (subfamily Esperidea). The trees show big dark green ovate leaves similar to those of lemon, star shaped white flowers and round yellow fruits. The botanical and geographical origins of this plant are still uncertain (Rapisarda and Germanò, 2013). It may be native of the Calabria region (Italy), as a result of mutations from other species. Alternatively, it may originate from Antilles, Greece, and the Canary Islands, from where Christopher Columbus imported it. The name "bergamot" seems to be derived from Berga, the Spanish city from which the plant was transported in Calabria (south of Italy) later. C. bergamia trees are cultivated almost exclusively along the southern coast of the Calabria region (more than 90% of the world production of bergamot comes from this region). However, small numbers of bergamot plants grow in other countries, such as Greece, Morocco, Iran and Ivory Coast, Argentina, and Brazil.

Citrus bergamia is defined as a hybrid between a sour orange (*C. aurantium* L.) and lemon (*C. limon* L. Burm. f.) or a mutation of the latter. Other authors considered it a hybrid between a sour orange and lime (*C. aurantifolia* [Christm. and Panzer] Swingle; Rapisarda and Germanò, 2013). Bergamot fruit is mainly used for its essential oils (bergamot essential oil: BEO) that are obtained by rasping and cold pressing the fruit peel. BEO is widely used in perfume, cosmetics, food, and confectionery industries for its intense fragrance and freshness. BEO is a greenish or brownish-yellow volatile oil (corresponding to the beginning and the end of the productive season) with a bitter aromatic taste and a characteristic pleasant odor. It is included in various countries' official Pharmacopoeias. However, bergamot juice, obtained from the endocarp after essential oils extraction, has long time been considered just a secondary and discarded product of the essential oil industry

Citrus bergamia Risso et Poiteau, also known as "Bergamot," is a plant belonging to the Rutaceae family, defined as a hybrid of bitter orange and lemon. It is an endemic plant of the Calabria region (Italy). Bergamot fruit is primarily used for the extraction of its essential oil (bergamot essential oil: BEO), employed in perfume, cosmetics, food, and confections. The aim of this review was to collect recent data from the literature on *C. bergamia* essential oil and, through a critical analysis, focus on safety and the beneficial effects on human health. Clinical studies on the therapeutic applications of BEO exclusively focus on the field of aromatherapy, suggesting that its use can be useful for reducing anxiety and stress.

Keywords: Citrus bergamia, bergamot essential oil, natural products, complementary and alternative medicine, aromatherapy

due to its bitter taste. Recently, it gained attention because of its hypolipemic and hypoglycaemic activity (Mollace et al., 2011), as well as its anti-inflammatory (Impellizzeri et al., 2014; Risitano et al., 2014) and anti-cancer properties (Delle Monache et al., 2013; Navarra et al., 2014; Visalli et al., 2014).

BEO CHEMICAL COMPOSITION

The chemical composition of BEO has been widely investigated and is well known (Costa et al., 2010; Dugo and Bonaccorsi, 2013). BEO contains several bioactive molecules with potential health benefits. It is composed of both a volatile (93-96% of total) and a non-volatile (4-7% of total) fraction. The first is mainly represented by monoterpene and sesquiterpene hydrocarbons, and their oxygenated derivatives, along with aliphatic aldehydes, alcohols, and esters (Dugo and Bonaccorsi, 2013). They include monoterpene limonene (25-53%) and high quantities of oxygenated compounds, such as linalool (2-20%), linalyl acetate (15-40%), yterpinene, and β -pinene (Mondello et al., 1998). The non-volatile fraction (4-7% of total) contains pigments, waxes, coumarins, and psoralens (such as 5-methoxypsoralen, also known as bergapten or 5-MOP, contained in about 0.2%), as well as bergamottine [5geranyloxypsoralen]) (Dugo et al., 2000). Due to the well-known 5-MOP-induced photo-toxicity, a furocoumarins-free essential oil has been prepared for perfumery and cosmetic uses. The vacuum distillation of bergamot peels provides a high-quality BEO totally devoid of 5-MOP that is chemically comparable to that of the cold-pressed oil (Belsito et al., 2007).

The characteristic flavor of *Citrus* oils is mainly provided by linalool, citral, and linalyl acetate, (Fang et al., 2004), whereas limonene and pinene are not much flavoring and they are relatively unstable compounds when exposed to heat and light. Thus, it is necessary to remove them to increase the shelf life of the products (Reverchon and Iacuzio, 1997; Fang et al., 2004).

BEO INDUSTRIAL AND MEDICINAL USES

Bergamot essential oil is one of the main basic constituents for the manufacture of perfumes, due to its ability to fix the aromatic bouquet of aromas and harmonize all of the essences, enhancing the fragrance. BEO is also used by the pharmaceutical industry, both to absorb the unpleasant smells of medicinal products and for its antiseptic and antibacterial properties. Finally, BEO is used in the food and confectionery industries as a flavoring.

In Italian folk medicine, it has been used primarily for fever and parasitic diseases, in addition to mouth, skin, respiratory and urinary tract infections, gonococcal infections, leucorrhoea, vaginal pruritus, tonsillitis, and sore throats (Pendino, 1998). For its antiseptic and antibacterial proprieties, BEO has been used as an antimicrobial agent to facilitate wound healing and has been included in preparations used to treat upper respiratory-tract disorders and hyperhidrosis. Moreover, BEO's use in magisterial, handcrafted, and homemade medicaments that were useful for skin disinfection, as well as use as an aid for healing minor wounds, has a long tradition in Italy. Currently, a furocoumarins-free BEO is used in preparations for cutaneous use.

Bergamot essential oil is widely employed in aromatherapy, and has recently received renewed popularity in improving mood and mild symptoms of stress-induced disorders (Halcon, 2002) and facilitating sleep induction (Wiebe, 2000). Aromatherapy massage has been shown to relieve symptoms of anxiety in patients with cancer (Wilkinson et al., 2007).

BIOLOGICAL ACTIVITIES OF BEO

ANTIMICROBIAL ACTIVITY

It has been reported that BEO has both antibacterial and antifungal activity against *Campylobacter jejuni, Escherichia coli* O157, *Listeria monocytogenes, Bacillus cereus*, and *Staphylococcus aureus* and dermatophytes, respectively (Karaca et al., 2007). The *in vitro* activity of BEO against *Candida species* suggests BEO's potential role in the topical treatment of *Candida infections* (Romano et al., 2005). BEO is also active against dermatophytes *in vitro* (Sanguinetti et al., 2007). Additionally, chitosan-based films containing BEO at 0.5, 1, 2, and 3% w/w showed a significant dose-dependent inhibitory effect on the growth of *Penicillium italicum* (Sánchez-González et al., 2010). Moreover, the *in vitro* effectiveness of the oil and vapors of bergamot and its components against common foodborne pathogens has been also investigated, and linalool was revealed to be the most effective anti-bacterial component (Fisher and Phillips, 2006).

ANTI-INFLAMMATORY ACTIVITY

Bergamot essential oil anti-inflammatory activity was demonstrated using the carrageenan-induced rat paw oedema test. The highest level of BEO anti-inflammatory activity was obtained with a 0.10 ml/kg dosage. The median effective dose of BEO was found to be 0.079 ml/kg (Karaca et al., 2007).

ANTIPROLIFERATIVE ACTIVITY

Bergamot essential oil has also been found to inhibit the survival and proliferation of SH-SY5Y neuroblastoma cells, (Celia et al., 2013) through the activation of multiple pathways leading to both necrotic and apoptotic cell death (Ursino et al., 2010). Moreover, Russo et al. (2013) showed that association of limonene and linalyl acetate, but not the exposure to the single compounds, caused significant cytotoxicity, suggesting for a major role of the combined action of these monoterpenes in cancer cell death induced by BEO.

NEUROPSYCHOPHARMACOLOGICAL AND NEUROPROTECTIVE ACTIVITIES

Anxiolytic effects of BEO (1.0, 2.5, and 5.0% w/w) were studied by administering it to rats subjected to anxiety-related behaviors, the elevated plus-maze and the hole-board tests, and then measuring the stress-induced levels of plasma corticosterone in comparison with the effects of diazepam. BEO (2.5%) and diazepam exhibited anxiolytic-like effects and attenuated the corticosterone response to acute stress (Saiyudthong and Marsden, 2010).

After perfusion into the hippocampus via the dialysis probe (20 μ l/20 min), BEO produced a dose-dependent and Ca²⁺-independent increase of extracellular aspartate, glycine, taurine, GABA, and glutamate (Morrone et al., 2007). Moreover, BEO (0.5 ml/kg) given intraperitoneally 1 h before experimental occlusion of the middle cerebral artery, significantly reduced infarct size after 24 h, especially in the medial striatum and the motor cortex, as revealed by 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) staining of tissue slices (Amantea et al., 2009).

Finally, in the human SH-SY5Y neuroblastoma cell line exposed to *N*-methyl-D-aspartate (NMDA), BEO (0.0005–0.01%) reduced the death of SH-SY5Y cells caused by 1 mM NMDA in a concentration dependent manner. In addition, 0.01% BEO counteracted the deactivation of Akt (a serine/threonine-specific protein kinase) and the consequent activation of glycogen synthase kinase 3 beta (GSK-3B) induced by NMDA. Results obtained with specific fractions of BEO, suggested that monoterpene hydrocarbons could be important for neuroprotection (Corasaniti et al., 2007).

ANALGESIC EFFECTS

Capsaicin-induced nociceptive responses in the plantar surface of the hindpaw were significantly reduced by intraplantar injection of BEO. Further experiments addressed the importance of linalool in BEO oil-induced antinociception (Sakurada et al., 2009). In another study, injection into the hindpaw of both the linalool and linalyl acetate compounds showed a significant reduction of nociceptive responses, which was much more potent than that induced by BEO. The enhanced effect of the association of BEO or linalool with morphine was antagonized by pretreatment with the opioid antagonist naloxone (Sakurada et al., 2011). The analgesic effect was also investigated using intraplantar injection of BEO or linalool in mice with neuropathic hypersensitivity induced by partial sciatic nerve ligation (PSNL). The results suggested that both BEO and linalool reduced PSNL-induced mechanical allodynia in a dose-dependent manner through a local effect. Moreover, the analgesic effect was associated with a reduction of spinal extracellular signal-regulated protein kinase (ERK) activation (Kuwahata et al., 2013).

CARDIOVASCULAR PROPERTIES

Bergamottine significantly decreased the electrocardiographic changes that are typical of coronary arterial spasms and the occurrence of experimental cardiac arrhythmias provoked by pitressin in guinea pigs. Bergamottine also increased the dose of ouabain required to cause ventricular premature beats, ventricular tachyarrhythmias, and death. These results indicate that bergamottine possesses potential antianginal and antiarrhythmic properties (Occhiuto and Circosta, 1996).

It is known that lectin-like oxyLDL receptor-1 (LOX-1) is involved in smooth muscle cell proliferation and neo-intima formation occurring in injured blood vessels. Interestingly, in an experimental model of rat angioplasty, pretreatment with the nonvolatile fraction of BEO, reduced the neointima proliferation in a dose-dependent manner, together with free radical formation and LOX-1 expression (Mollace et al., 2008). Moreover, it has been suggested that BEO induces vasorelaxation of the mouse aorta by activating K⁺ channels and inhibiting Ca²⁺ influx (Kang et al., 2013), which differentially modulates intracellular Ca²⁺ levels in vascular endothelial and smooth muscle cells (You et al., 2013). These findings indicate that BEO could be further studied for its potential role as a vasodilator agent in cardiovascular diseases.

CLINICAL STUDIES

The scientific rationale of essential oils use in aromatherapy to improve mood and the mild symptoms of stress disorders, such as anxiety, depression, and chronic pain, is supported by both the physiological and psychological effects caused by the inhalation of volatile components that are believed to act via limbic system structures, such as the hippocampal formation, the hypothalamus and the pyriform cortex. Indeed, several clinical and experimental data indicate that aromatherapy can improve mood, alertness, and cognition. Specific EEG changes associated with alertness and relaxation have been observed in some studies using essential oils. With regard to BEO, these effects have been attributed to volatile components other than 5-MOP (Bagetta et al., 2010). Although the mechanisms by which BEO induces its effects on the central nervous system have not yet been fully understood, it has been suggested that they could be mediated by the release of amino acids that interact with mechanisms that modulate synaptic plasticity (see neuropsychopharmacological and neuroprotective activities section).

Clinical research focused essentially on the therapeutic application of BEO in aromatherapy, by inhalation or hand massage, on anxiety and stress responses. We reviewed the results of ten clinical studies in which only two reported negative results. Their principal data are reported in Table 1. Four studies evaluated the effects of different essential oil combinations, with BEO being a constituent of the mixture associated with lavender (Lavandula angustifolia), cedarwood (Cedrus atlantica), ylang ylang (Cananga odorata) or frankincense (Boswellia carteri; Graham et al., 2003; Hwang, 2006; Chang, 2008; Hongratanaworakit, 2011). Among the studies with combinations, only Graham et al.'s (2003) study reported negative results. The other three studies showed positive effects based on the subjective responses to stress. The remaining six studies were all conducted using only BEO. Five of these studies reported beneficial effects from BEO, such as reduced heart rate, blood pressure and stress responses (Peng et al., 2009; Seo, 2009; Chang and Shen, 2011; Liu et al., 2013; Ni et al., 2013). One study investigating the effects of aromatherapy with BEO on pain and nausea of children and adolescents undergoing stem cell transplantation, showed no benefit. Unfortunately, most of clinical trials did not report the quality parameters of the essential oils used. Even though these studies are not always satisfactory from a methodological point of view, they show that employment of BEO in aromatherapy can be useful for reducing anxiety and stress responses, and it deserves further clinical investigation.

PRE-CLINICAL SAFETY OF BEO

Bergamot essential oil is a widely used aromatic ingredient in cosmetics that may be applied on sun-exposed skin areas, although components such as bergapten, citropten, bergamotene, and other furocoumarins may cause phototoxic effects (Chouchi et al., 1996; Kejlovà et al., 2007). Indeed, psoralen can induce skin cancer due to the formation of covalent DNA adducts by exposure to ultraviolet A or solar light (Bakkali et al., 2008). On the contrary, it was reported the photochemoprotection from UVR-induced DNA damage by bergapten (Chadwick et al., 1994). Primarily due to the presence of psoralens, BEO preparations may pose phototoxic, genotoxic and carcinogenic risks. However, a layer of oil on the skin has no sensitizing effect, if not rubbed in, and it has been showed as BEO alone does not irritate the skin (Oppenheim, 1947). Moreover, Trombetta et al. (2010) studied the genotoxic activity of ethanolic bergamot extracts in the SOS (group of cellular functions) chromotest (a bacterial test for detecting DNA-damaging agents), which employs the error-prone DNA repair pathway of E. coli PQ37. The experimental results suggested that the extracts, used at doses up to 50 µg/assay, do not induce genotoxicity, even when undergoing metabolic activation. However, in order to guarantee safety, bergapten and other phototoxic components should be removed from BEO, thus resulting a furocoumarin-free BEO. Its use in cutaneous preparations can be considered safe, having no risk of such skin reactions (Belsito et al., 2007). However, safety issues are not separate from the quality aspects regarding the purity of the essential oil or the presence of adulterants. Analysis of BEO authenticity can be performed using enantioselective gas-chromatography (Schipilliti et al., 2011).

ADVERSE EFFECTS

Despite its wide application, there are only a few reports of phototoxic reactions caused by aromatherapy with BEO. Freund, in 1916, was the first to describe a series of four cases of intense pigmentation in irregular areas after the use of Eau de Cologne before exposure to sunshine. He observed the same phenomenon after experimental use of BEO, one of the constituents of Eau de Cologne. Rosenthal first used the term "Berloque dermatitis" because of the form of the resulting pigmentation (Oppenheim, 1947). Hyperpigmentation of the neck, face, arms, or trunk that have been exposed to light has been attributed to psoralens in the BEO. Cases have become much more rare since the introduction of psoralen-free BEO.

Bergamot essential oil rich in 5-MOP has been used as sun tanning products for many years. In 1995, this use was banned and limited to the treatment of certain skin disorders. Toxic reactions can occur due to psoralen or UVA overdosing or due to accidental exposure to additional UVA, including sunlight exposure.

Authors	Study type	Essential oils	Subjects	Principal endpoints	Outcome
Graham et al.	Double-blind	Lavender, bergamot,	200 patients undergoing	Anxiety measured by HADS	Negative results
(2003)	placebo-controlled randomized	and cedarwood by	radiotherapy		
		inhalation			
Hwang (2006)	Placebo-controlled randomized	Lavender, ylang ylang,	52 subjects affected by	Blood pressure, serum cortisol levels,	Reduction of psychological stress
		and bergamot by	hypertension	catecholamine levels	responses, serum cortisol levels,
		inhalation			blood pressure
Chang (2008)	Controlled (non-equivalent	Bergamot, Lavender,	58 hospice patients with terminal	Pain, depression scales	Reduction of pain and depression
	control group)	and Frankincense by	cancer		
		hand massage			
Peng et al. (2009)	Open-label randomized	Bergamot by inhalation	114 healthy undergraduate	Heart rate variability	Reduction of heart rate
	controlled trial		students		
Seo (2009)	Placebo-controlled, cross-over	Bergamot by inhalation	36 female high school students	Blood pressure, pulse rate, IgA levels	Reduction of blood pressure and
					heart rate, no effects on IgA levels
Hongratanaworakit	Controlled, randomized	Bergamot, lavender	40 healthy subjects	Blood pressure, pulse rate, breathing	Decrease of subjective behavioral
(2011)		cutaneous application		rate, and skin temperature, recorded	arousal
				as indicators of the arousal level of	
				the ANS	
Chang and Shen	Not controlled	Bergamot by inhalation	54 elementary school teachers	Blood pressure, heart rate	Decreases in blood pressure and
(2011)					heart rate
Ndao etal. (2012)	Double-blind,	Bergamot by inhalation	40 children/adolescents to	Pain and nausea scales	No benefit
	placebo-controlled randomized		undergo Stem cell transplantation		
Ni etal. (2013)	Placebo-controlled,	Bergamot by inhalation	116 patients awaiting ambulatory	Responses to the (STAI) score and	Reduction of anxiety, heart rate,
	randomized		surgery	vital signs	variability and blood pressure
Liu etal. (2013)	Placebo-controlled, no	Bergamot by inhalation	29 elementary work stressed	Blood pressure, heart rate	Reduction of heart rate
	randomization		schoolteachers		

Skin application of psoralens is more likely to induce photosensitivity reactions. To avoid the phototoxic and photocarcinogenic harm, the International Fragrance Association (IFRA) recommended that products that are applied in areas of skin exposed to the sun not have to contain more than 0.4% of BEO. The occurrence of second-degree skin burns was found in two women after PUVA exposure (Herr et al., 2007).

The cases of the two patients were described as having localized and disseminated bullous phototoxic skin reactions that developed 48–72 h after ultraviolet exposure subsequent to aromatherapy with BEO. The first case was of a woman that had used a bergamot aromatherapy oil preparation 3 days earlier and subsequently stayed exposed to the sun for several hours. In the second case, the woman visited a sauna 2 days before, where she was exposed to aromatherapy with BEO before being exposed to UVA radiation while tanning. Cutaneous lesions developed gradually within 48– 72 h. In both cases, the patients did not use other creams and/or medications at the same time (Kaddu et al., 2001).

In another case, a 44-year-old man drank up to 4 L of black tea every day for 25 years. When he changed his brand because of occasional gastric pain, he began to drink the same daily quantity of Earl Gray tea. One week after the change, he noticed repeated muscle cramps. After 5 weeks of drinking the tea, the muscle cramps continued. Occasionally, he observed fasciculations, distal paraesthesia, and feelings of pressure in his eyes that were associated with blurred vision. Neurological examination confirmed reduced visual acuity and fasciculations. After 5 months, suspecting a relation between his symptoms and his tea intake, he stopped drinking Earl Gray, going back to black tea. Within 1 week, the symptoms completely disappeared. Successively, he observed that the symptoms did not appear if he ingested no more than 1 L of Earl Gray tea each day. Earl Gray tea is composed of black tea and BEO. The adverse effects of BEO in this patient could be explained by the potential effects of bergapten as a selective axolemmal potassium channel blocker, reducing potassium permeability at the nodes of Ranvier in a time-dependent manner. This may provoke hyperexcitability of the axonal membrane and phase alterations of potassium currents, producing fasciculation and muscle cramps. Impairment of the potassium channel function plays a pathogenic role in other disorders characterized by the occurrence of fasciculation. Prolonged opening of voltage-gated sodium channels caused by bergapten may enhance neuronal hyperexcitability (Finsterer, 2002).

CONCLUSION

Bergamot essential oil has been traditionally used in Italian folk medicine for magisterial, handcrafted, and homemade preparations that are intended for topical use as antiseptics for the disinfection of skin and as aids for healing minor wounds. BEO is generally well tolerated, but it possesses photosensitive properties because of the presence of furocoumarins, especially 5-MOP. Therefore, in topical preparations, psoralen-free essential oil was used in recent decades. As a consequence of this and because of safety concerns related to furocoumarins, the use of high quality controlled psoralen-free BEO is recommended as a general precaution. However, although the oil has been used extensively for many years, there have only been a few reports of phototoxic reactions to bergamot aromatherapy oil.

Several biological activities of BEO were shown, such as antimicrobial, anti-inflammatory, antiproliferative, and analgesic effects, including effects on the central nervous and cardiovascular systems. Even though these effects indicate potential clinical applications for BEO in the future, to date, only clinical studies investigating aromatherapy effects have been published. The latter were carried out primarily to investigate anxiolytic effects and the reduction of stress responses. They indicate that treatment with BEO in aromatherapy can be useful to reduce anxiety and stress effects.

REFERENCES

- Amantea, D., Fratto, V., Maida, S., Rotiroti, D., Ragusa, S., Nappi, G., et al. (2009). Prevention of glutamate accumulation and upregulation of phospho-akt may account for neuroprotection afforded by bergamot essential oil against brain injury induced by focal cerebral ischemia in rat. *Int. Rev. Neurobiol.* 5, 389–405. doi: 10.1016/S0074-7742(09)85027-7
- Bagetta, G., Morrone, L. A., Rombolà, L., Amantea, D., Russo, R., Berliocchi, L., et al. (2010). Neuropharmacology of the essential oil of bergamot. *Fitoterapia* 81, 453–461. doi: 10.1016/j.fitote.2010.01.013
- Bakkali, F., Averbeck, S., Averbeck, D., and Idaomar, M. (2008). Biological effects of essential oils – a review. *Food Chem. Toxicol.* 46, 446–475. doi: 10.1016/j.fct.2007.09.106
- Belsito, E. L., Carbone, C., Di Gioia, M. L., Leggio, A., Liguori, A., Perri, F., et al. (2007). Comparison of the volatile constituents in cold-pressed bergamot oil and a volatile oil isolated by vacuum distillation. *J. Agric. Food Chem.* 55, 7847–7851. doi: 10.1021/jf070997q
- Celia, C., Trapasso, E., Locatelli, M., Navarra, M., Ventura, C. A., Wolfram, J., et al. (2013). Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells. *Colloids Surf. B Biointerfaces* 112, 548–553. doi: 10.1016/j.colsurfb.2013.09.017
- Chadwick, C. A., Potten, C. S., Cohen, A. J., and Young, A. R. (1994). The time of onset and duration of 5-methoxypsoralen photochemoprotection from UVRinduced DNA damage in human skin. *Br. J. Dermatol.* 131, 483–494. doi: 10.1111/j.1365-2133.1994.tb08548.x
- Chang, K. M., and Shen, C. W. (2011). Aromatherapy benefits autonomic nervous system regulation for elementary school faculty in taiwan. *Evid. Based Complement. Alternat. Med.* 2011, 946537. doi: 10.1155/2011/946537
- Chang, S. Y. (2008). Effects of aroma hand massage on pain, state anxiety and depression in hospice patients with terminal cancer. *Taehan Kanho Hakhoe Chi.* 38, 493–502. doi: 10.4040/jkan.2008.38.4.493
- Chouchi, D., Barth, D., Reverchon, E., and Della Porta, G. (1996). Supercritical desorption of bergamot peel oil. *Znd. Eng. Chem. Res.* 34, 4508–4513. doi: 10.1021/ie00039a043
- Corasaniti, M. T., Maiuolo, J., Maida, S., Fratto, V., Navarra, M., Russo, R., et al. (2007). Cell signaling pathways in the mechanisms of neuroprotection afforded by bergamot essential oil against NMDA-induced cell death in vitro. *Br. J. Pharmacol.* 151, 518–529. doi: 10.1038/sj.bjp.0707237
- Costa, R., Dugo, P., Navarra, M., Raymo, V., Dugo, G., and Mondello, L. (2010). Study on the chemical composition variabilità of some processed bergamot (*Citrus bergamia*) essential oils. *Flavour Fragr. J.* 25, 4–12. doi: 10.1002/ffj.1949
- Delle Monache, S., Sanità, P., Trapasso, E., Ursino, M. R., Dugo, P., Russo, M., et al. (2013). Mechanisms underlying the anti-tumoral effects of *Citrus Bergamia* juice. *PLoS ONE* 8:e61484. doi: 10.1371/journal.pone.0061484
- Dugo, G., and Bonaccorsi, I. (2013). *Citrus Bergamia: Bergamot and its derivatives*. Boka Raton, FL: CCR Press.
- Dugo, P., Mondello, L., Dugo, L., Stancanelli, R., and Dugo, G. (2000). LC-MS for the identification of oxygen heterocyclic compounds in Citrus essential oils. *J. Pharm. Biomed. Anal.* 24, 147–150. doi: 10.1016/S0731-7085(00)00400-3
- Fang, T., Goto, M., Sasaki, M., and Hirose, T. (2004). Combination of supercritical CO2 and vacuum distillation for the fractionation of bergamot oil. J. Agric. Food Chem. 52, 5162–5167. doi: 10.1021/jf049895f
- Finsterer, J. (2002). Earl Grey tea intoxication. *Lancet* 359, 1484. doi: 10.1016/S0140-6736(02)08436-2

- Fisher, K., and Phillips, C. A. (2006). The effect of lemon, orange and bergamot essential oils and their components on the survival of *Campylobacter jejuni*, *Escherichia coli* O157, *Listeria monocytogenes*, *Bacillus cereus* and *Staphylococcus aureus* in vitro and in food systems. *J. Appl. Microbiol.* 101, 1232–1240. doi: 10.1111/j.1365-2672.2006.03035.x
- Graham, P. H., Browne, L., Cox, H., and Graham, J. (2003). Inhalation aromatherapy during radiotherapy: results of a placebo-controlled double-blind randomized trial. *J. Clin. Oncol.* 21, 2372–2376. doi: 10.1200/JCO.2003. 10.126
- Halcon, L. L. (2002). Aromatherapy: therapeutic applications of plant essential oils. *Minnesota Med.* 85, 42–46.
- Herr, H., Cho, H. J., and Yu, S. (2007). Burns caused by accidental overdose of photochemotherapy (PUVA). Burns 33, 372–375. doi: 10.1016/j.burns.2006.07.005
- Hongratanaworakit, T. (2011). Aroma-therapeutic effects of massage blended essential oils on humans. *Nat. Prod. Commun.* 6, 1199–1204.
- Hwang, J. H. (2006). The effects of the inhalation method using essential oils on blood pressure and stress responses of clients with essential hypertension. *Taehan Kanho Hakhoe Chi* 36, 1123–1134.
- Impellizzeri, D., Bruschetta, G., Di Paola, R., Ahmad, A., Campolo, M., Cuzzocrea, S., et al. (2014). The anti-inflammatory and antioxidant effects of bergamot juice extract (BJe) in an experimental model of inflammatory bowel disease. *Clin Nutr.* doi: 10.1016/j.clnu.2014.11.012 [Epub ahead of print].
- Kaddu, S., Kerl, H., and Wolf, P. (2001). Accidental bullous phototoxic reactions to bergamot aromatherapy oil. J. Am. Acad. Dermatol. Brief reports. 45, 458–461. doi: 10.1067/mjd.2001.116226
- Kang, P., Suh, S. H., Min, S. S., and Seol, G. H. (2013). The essential oil of *Citrus bergamia* Risso induces vasorelaxation of the mouse aorta by activating K+ channels and inhibiting Ca2+ influx. *J. Pharm. Pharmacol.* 65, 745–749. doi: 10.1111/jppp.12031
- Karaca, M., Özbek, H., Him, A., Tütüncü, M., Akkan, H. A., and Kaplanoğlu, V. (2007). Investigation of anti-inflammatory activity of bergamot oil. *Eur. J. Gen. Med.* 4, 176–179.
- Kejlovà, K., Jìrovà, D., Bendovà, H., Kandàrovà, H., Weidenhoffer, Z., Kolàrova, H., et al. (2007). Phototoxicity of bergamot oil assessed by in vitro techniques in combination with human patch tests. *Toxicol. Vitro.* 21, 1298–1303. doi: 10.1016/j.tiv.2007.05.016
- Kuwahata, H., Komatsu, T., Katsuyama, S., Corasaniti, M. T., Bagetta, G., Sakurada, S., et al. (2013). Peripherally injected linalool and bergamot essential oil attenuate mechanical allodynia via inhibiting spinal ERK phosphorylation. *Pharmacol. Biochem. Behav.* 103, 735–741. doi: 10.1016/j.pbb.2012. 11.003
- Liu, S. H., Lin, T. H., and Chang, K. M. (2013). The physical effects of aromatherapy in alleviating work-related stress on elementary school teachers in taiwan. *Evid. Based Complement. Alternat. Med.* 2013, 853809. doi: 10.1155/2013/8 53809
- Mollace, V., Ragusa, S., Sacco, I., Muscoli, C., Sculco, F., Visalli, V., et al. (2008). The protective effect of bergamot oil extract on lecitine-like oxyLDL receptor-1 expression in balloon injury-related neointima formation. *J. Cardiovasc. Pharmacol. Ther.* 13, 120–129. doi: 10.1177/1074248407313821
- Mollace, V., Sacco, I., Janda, E., Malara, C., Ventrice, D., Colica, C., et al. (2011). Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. *Fitoterapia* 82, 309–316. doi: 10.1016/j.fitote.2010.10.014
- Mondello, L., Verzera, A., Previti, P., Crispo, F., and Dugo, G. (1998). Multidimensional capillary GC-GC for the analysis of complex samples. 5. enantiomeric distribution of monoterpene hydrocarbons, monoterpene alcohols, and linalyl acetate of bergamot (*Citrus bergamia* Risso et Poiteau) Oils. J. Agric. Food Chem. 46, 4275–4282. doi: 10.1021/jf980228u
- Morrone, L. A., Rombolà, L., Pelle, C., Corasaniti, M. T., Zappettini, S., Paudice, P., et al. (2007). The essential oil of bergamot enhances the levels of amino acid neurotransmitters in the hippocampus of rat: implication of monoterpene hydrocarbons. *Pharmacol. Res.* 55, 255–262. doi: 10.1016/j.phrs.2006.11.010
- Navarra, M., Ursino, M. R., Ferlazzo, N., Russo, M., Schumacher, U., and Valentiner, U. (2014). Effect of *Citrus bergamia* juice on human neuroblastoma cells in vitro and in metastatic xenograft models. *Fitoterapia* 95, 83–92. doi: 10.1016/j.fitote.2014.02.009
- Ndao, D. H., Ladas, E. J., Cheng, B., Sands, S. A., Snyder, K. T., and Garvin, J. H. Jr. (2012). Inhalation aromatherapy in children and adolescents undergoing stem

cell infusion: results of a placebo-controlled double-blind trial. *Psychooncology* 21, 247–254. doi: 10.1002/pon.1898

- Ni, C. H., Hou, W. H., Kao, C. C., Chang, M. L., Yu, L. F., Wu, C. C., et al. (2013). The anxiolytic effect of aromatherapy on patients awaiting ambulatory surgery: a randomized controlled trial. *Evid. Based Complement. Alternat. Med.* 2013, 927419. doi: 10.1155/2013/927419
- Occhiuto, F., and Circosta, C. (1996). Antianginal and antiarrhythmic effects of bergamottine, a furocoumarin isolated from bergamot oil. *Phytother. Res.* 10, 491–496. doi: 10.1002/(SICI)1099-1573(199609)10:6<491::AID-PTR889>3.0. CO;2-T
- Oppenheim, M. (1947). Local sensitization of the skin to Grenz rays by bergamot oil. J. Invest. Dermatol. 8, 255–262. doi: 10.1038/jid.1947.37
- Pendino, G. M. (1998). Il bergamotto in terapia medica: attualità e prospettive. Ess. Deriv. Agr. 68, 57–62.
- Peng, S. M., Koo, M., and Yu, Z. R. (2009). Effects of music and essential oil inhalation on cardiac autonomic balance in healthy individuals. J. Altern. Complement. Med. 15, 53–57. doi: 10.1089/acm.2008.0243
- Rapisarda, A., and Germanò, M. P. (2013). "Citrus bergamia risso and poiteau botanical classification, morphology and anatomy," in Citrus bergamia: Bergamot and its Derivatives, eds G. Dugo and I. Bonaccorsi (Boka Raton, FL: CCR Press), 9–11.
- Reverchon, E., and Iacuzio, G. (1997). Supercritical desorption of bergamot peel oil from silica gel experiments and mathematical modelling. *Chem. Eng. Sci.* 52, 3553–3559. doi: 10.1016/S0009-2509(97)00177-2
- Risitano, R., Currò, M., Cirmi, S., Ferlazzo, N., Campiglia, P., Caccamo, D., et al. (2014). Flavonoid fraction of *Bergamot juice* reduces LPSinduced inflammatory response through SIRT1-mediated NF-κB inhibition in THP-1 monocytes. *PLoS ONE* 9:e107431. doi: 10.1371/journal.pone.01 07431
- Romano, L., Battaglia, F., Masucci, L., Sanguinetti, M., Posteraro, B., Plotti, G., et al. (2005). In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates. *J. Antimicrob. Chemother.* 55, 110–114. doi: 10.1093/jac/ dkh503
- Russo, R., Ciociaro, A., Berliocchi, L., Cassiano, M. G., Rombolà, L., Ragusa, S., et al. (2013). Implication of limonene and linalyl acetate in cytotoxicity induced by bergamot essential oil in human neuroblastoma cells. *Fitoterapia* 89, 48–57. doi: 10.1016/j.fitote.2013.05.014
- Saiyudthong, S., and Marsden, C. A. (2010). Acute effects of bergamot oil on anxietyrelated behaviour and corticosterone level in rats. *Phytother. Res.* 25, 858–862. doi: 10.1002/ptr.3325
- Sakurada, T., Kuwahata, H., Katsuyama, S., Komatsu, T., Morrone, L. A., Corasaniti, M. T., et al. (2009). Intraplantar injection of bergamot essential oil into the mouse hindpaw: effects on capsaicin-induced nociceptive behaviors. *Int. Rev. Neurobiol.* 85, 237–248. doi: 10.1016/S0074-7742(09) 85018-6
- Sakurada, T., Mizoguchi, H., Kuwahata, H., Katsuyama, S., Komatsu, T., Morrone, L. A., et al. (2011). Intraplantar injection of bergamot essential oil induces peripheral antinociception mediated by opioid mechanism. *Pharmacol. Biochem. Behav.* 97, 436–443. doi: 10.1016/j.pbb.2010.09.020
- Sánchez-González, L., Chafer, M., Chiralt, A., and Gonzalez-Martinez, C. (2010). Physical properties of edible chitosan films containing bergamot essential oil and their inhibitory action on *Penicillium italicum. Carbohydrate Polymers* 82, 277–283. doi: 10.1016/j.carbpol.2010.04.047
- Sanguinetti, M., Posteraro, B., Romano, L., Battaglia, F., Lo Pizzo, T., De Carolis, E., et al. (2007). In vitro activity of *Citrus bergamia* (bergamot) oil against clinical isolates of dermatophytes. *J. Antimicrob. Chemother.* 59, 305–308. doi: 10.1093/jac/dkl473
- Schipilliti, L., Dugo, P., Santi, L., Dugo, G., and Mondello, L. (2011). Authentication of bergamot essential oil by gas-chromatography-combustion-isotope ratio mass spectrometer (GC-C-IRMS). J. Essent. Oil Res. 23, 60–71.
- Seo, J. Y. (2009). The effects of aromatherapy on stress and stress responses in adolescents. J. Korean Acad. Nurs. 39, 357–365. doi: 10.4040/jkan.2009.39. 3.357
- Trombetta, D., Cimino, F., Cristani, M., Mandalari, G., Saija, A., Ginestra, G., et al. (2010). In vitro protective effects of two extracts from bergamot peels on human endothelial cells exposed to tumor necrosis factor-r (TNF-r). *J. Agric. Food Chem.* 58, 8430–8436. doi: 10.1021/jf1008605

- Ursino, M. R., Trapasso, E., Calapai, G., Bramanti, P., and Navarra, M. (2010). Effects of bergamot essential oil and its extractive fractions on SH-SY5Y human neuroblastoma cell growth. *Basic Clin. Pharmacol. Toxicol.* 107, 627.
- Visalli, G., Ferlazzo, N., Cirmi, S., Campiglia, P., Gangemi, S., Pietro, A. D., et al. (2014). Bergamot juice extract inhibits proliferation by inducing apoptosis in human colon cancer cells. *Anticancer Agents Med. Chem.* 14, 1402–1413. doi: 10.2174/1871520614666140829120530
- Wiebe, E. (2000). A randomized trial of aromatherapy to reduce anxiety before abortion. *Eff. Clin. Pract.* 3, 166–169.
- Wilkinson, S. M., Love, S. B., Westcombe, A. M., Gambles, M. A., Burgess, C. C., and Cargill, A. (2007). Effectiveness of aromatherapy massage in the management of anxiety and depression in patients with cancer. A multicenter randomized controlled trial. J. Clin. Oncol. 25, 532–539. doi: 10.1200/JCO.2006.08.9987
- You, J. H., Kang, P., Min, S. S., and Seol, G. H. (2013). Bergamot essential oil differentially modulates intracellular Ca2+ levels in vascular endothelial and smooth muscle cells: a new finding seen with fura-2. *J. Cardiovasc. Pharmacol.* 61, 324–328. doi: 10.1097/FJC.0b013e3182834681

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 16 September 2014; accepted: 11 February 2015; published online: 02 March 2015.

Citation: Navarra M, Mannucci C, Delbò M and Calapai G (2015) Citrus bergamia essential oil: from basic research to clinical application. Front. Pharmacol. **6**:36. doi: 10.3389/fphar.2015.00036

This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology.

Copyright © 2015 Navarra, Mannucci, Delbò and Calapai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.